Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer

Urology

Volumn 56, Issue 6, 2000, Pages 988-993

  Sodee, D B ^a,c   Malguria, N ^a   Faulhaber, P ^a   Resnick, M I ^a   Albert, J ^b   Bakale, G ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPROMAB PENDETIDE IN 111; INDIUM CHLORIDE IN 111; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SCINTISCANNING; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PELVIS LYMPH NODE; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY; RETROSPECTIVE STUDY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANTIBODIES, MONOCLONAL; HUMANS; INDIUM RADIOISOTOPES; LOGISTIC MODELS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; NEOPLASM METASTASIS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIONUCLIDE IMAGING; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0033663460     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(00)00824-4     Document Type: Article

References (30)

1. Cancer statistics, 2000
2. Observations on the early detection of prostate cancer from the American Cancer Society National Prostate Cancer Detection Project
3. Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers
4. Prostate-specific membrane antigen expression in normal and malignant human prostate tissues
5. Prostate-specific membrane antigen (PSMA): Current benefits and future value
6. Prostate-specific membrane antigen: Present and future applications
7. Monoclonal antibody imaging of occult prostate cancer in patients with elevated prostate-specific antigen positron emission tomography and biopsy correlation
8. Comparison of serum PSMA, PSA levels with results of Cytogen-356 ProstaScint scanning in prostate cancer patients
9. Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide
10. ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation or hormone therapy: Analysis of 136 scans of 100 patients
11. Prostate cancer and prostate bed SPECT imaging with ProstaScint: Semi-quantitative correlation with prostatic biopsy results
12. 111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy
13. Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy
14. Immunoscintigraphy with indium-111-capromab pendetide: Evaluation before definitive therapy in patients with prostate cancer
15. 111indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients
16. Follow-up ProstaScint scans verify detection of occult soft-tissue recurrence after failure of primary prostate cancer therapy
17. Staging errors in clinically localized prostatic cancer
18. Sensitivity and specificity of sextant biopsies in the detection of prostate cancer: Preliminary report
19. The effectiveness of imaging modalities in clinical staging of localized prostate cancer
20. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases
21. Optimization of ProstaScint sensitivity in the diagnosis and staging of prostate cancer
22. Lack of correlation between prostate-specific antigen and the presence of measurable soft tissue metastasis in hormone-refractory prostate cancer
23. PSA decline is an independent prognostic marker in hormonally treated prostate cancer
24. Indium-111 capromab pendetide (ProstaScint) imaging to detect recurrent and metastatic prostate cancer
25. The National Cancer Database report on prostate cancer following the peak in incidence rates in the United States
26. Two different lymph node metastasis patterns of a prostate cancer
27. Radiolabeled monoclonal antibody indium 111-labeled CYT-365 localizes extra-prostatic recurrent carcinoma after prostatectomy
28. Considerations regarding prostate biopsies
29. Logistic regression analysis combining serum PSA, Gleason score, and monoclonal antibody scan (ProstaScint) to predict lymph nodal involvement in prostate cancer
30. Who needs lymph node dissection as a staging procedure in prostate cancer?